ES2125977T3 - Cdw52-anticuerpo especifico para el tratamiento de la inflamacion de las articulaciones mediada por celulas t. - Google Patents

Cdw52-anticuerpo especifico para el tratamiento de la inflamacion de las articulaciones mediada por celulas t.

Info

Publication number
ES2125977T3
ES2125977T3 ES93908763T ES93908763T ES2125977T3 ES 2125977 T3 ES2125977 T3 ES 2125977T3 ES 93908763 T ES93908763 T ES 93908763T ES 93908763 T ES93908763 T ES 93908763T ES 2125977 T3 ES2125977 T3 ES 2125977T3
Authority
ES
Spain
Prior art keywords
treatment
cdw52
cells
specific antibody
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93908763T
Other languages
English (en)
Inventor
Herman Waldmann
Geoffrey Hale
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BTG International Ltd
Original Assignee
BTG International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929215749A external-priority patent/GB9215749D0/en
Application filed by BTG International Ltd filed Critical BTG International Ltd
Application granted granted Critical
Publication of ES2125977T3 publication Critical patent/ES2125977T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)

Abstract

LA INVENCION SE REFIERE AL USO DE UN ANTICUERPO QUE RECONOCE EL ANTIGENO CDW52 PARA EL TRATAMIENTO DE LAS INFLAMACIONES DE LAS ARTICULACIONES INTERMEDIADAS POR LAS CELULAS T, EN PARTICULAR PARA EL TRATAMIENTO DE LA ARTRITIS REUMATOIDE. PREFERIBLEMENTE EL ANTICUERPO ES EL ANTICUERPO HUMANIZADO CAMPATH-1H QUE PUEDE USARSE JUNTO CON OTRO ANTICUERPO INMUNOSUPRESOR O UN AGENTE INMUNOSUPRESOR TAL COMO UN ESTEROIDE.
ES93908763T 1991-10-15 1992-10-14 Cdw52-anticuerpo especifico para el tratamiento de la inflamacion de las articulaciones mediada por celulas t. Expired - Lifetime ES2125977T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77559891A 1991-10-15 1991-10-15
GB929215749A GB9215749D0 (en) 1992-07-24 1992-07-24 Medicaments

Publications (1)

Publication Number Publication Date
ES2125977T3 true ES2125977T3 (es) 1999-03-16

Family

ID=26301317

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93908763T Expired - Lifetime ES2125977T3 (es) 1991-10-15 1992-10-14 Cdw52-anticuerpo especifico para el tratamiento de la inflamacion de las articulaciones mediada por celulas t.

Country Status (12)

Country Link
EP (1) EP0610447B1 (es)
JP (1) JP3535155B2 (es)
KR (1) KR100264218B1 (es)
AT (1) ATE174515T1 (es)
AU (1) AU671807B2 (es)
CA (1) CA2120911A1 (es)
DE (1) DE69227918T2 (es)
DK (1) DK0610447T3 (es)
ES (1) ES2125977T3 (es)
IL (1) IL103418A (es)
MY (1) MY115415A (es)
WO (1) WO1993007899A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
GB9603507D0 (en) * 1996-02-20 1996-04-17 Isis Innovation Antibody variants
GB2380127A (en) 2001-09-26 2003-04-02 Isis Innovation Treatment of chronic joint inflammation
SG10201806573TA (en) * 2012-05-25 2018-09-27 Cellectis Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0328404B1 (en) * 1988-02-12 1993-09-29 Btg International Limited Modified antibodies
JPH05502586A (ja) * 1989-12-27 1993-05-13 セントカー・インコーポレーテツド Ｃｄ４受容体に対するキメラ免疫グロブリン
GB9022547D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Purified immunoglobulin

Also Published As

Publication number Publication date
AU2698592A (en) 1993-05-21
DE69227918D1 (de) 1999-01-28
AU671807B2 (en) 1996-09-12
JP3535155B2 (ja) 2004-06-07
IL103418A0 (en) 1993-03-15
WO1993007899A1 (en) 1993-04-29
CA2120911A1 (en) 1993-04-29
DK0610447T3 (da) 1999-08-23
KR100264218B1 (ko) 2000-08-16
DE69227918T2 (de) 1999-05-12
ATE174515T1 (de) 1999-01-15
JPH07500330A (ja) 1995-01-12
MY115415A (en) 2003-06-30
EP0610447B1 (en) 1998-12-16
IL103418A (en) 1997-11-20
EP0610447A1 (en) 1994-08-17

Similar Documents

Publication Publication Date Title
DK0662148T3 (da) Monoklonale antistoffer, som er reaktive med definerede regioner af T-celleantigenreceptoren
ATE233814T1 (de) Humaner neutralisierender monoklonaler antikörper gegen den die immunschwäche beim menschen hervorringenden virus
DK0616537T3 (da) CDw52-specifikt antistof til behandling af dissemineret sclerose
EA200200503A1 (ru) Способ лечения ревматоидного артрита
DK0626447T3 (da) Monoklonale antistoffer og Fv, som er specifikke for CD2-antigen
AR001811A1 (es) Anticuerpos anti-icam-1 modificados y su uso en eltratamiento de inflamaciones
WO1990010709A3 (en) Monoclonal antibodies for metallic cations on small molecules
DE69032979D1 (de) Bispezifische heteroantikörper mit zweifachen effektorfunktionen
EA200400930A1 (ru) Блокирующее моноклональное антитело к vla-1 или его применение для лечения воспалительных заболеваний
ES2125977T3 (es) Cdw52-anticuerpo especifico para el tratamiento de la inflamacion de las articulaciones mediada por celulas t.
DK407987A (da) Apolipoprotein b-specifikke monoklonale antistoffer og hybridomer, som producerer disse antistoffer
EP0340604A3 (en) Monoclonal antibody and its use
NO981272L (no) Humanisert anti-human-Fas-antistoff
SE8702734D0 (sv) Monoclonal antibodies to pseudomonas aeruginosa flagella
AU584690B2 (en) E87ag antigen of pseudomonas aeruginosa, monoclonal antibody against it, and hybridoma
NO972522L (no) Monoklonale antistoffer med immunoundertrykkende aktivitet
ES8800052A1 (es) Un procedimiento para preparar una proteina de superficie antigenica de anaplasma marginale
DK592086A (da) Humant conglutinin
DE69326347D1 (de) Neuartiges endothelzell-molekül, das die bindung von lymphozyten im menschen vermittelt
EP0450573A3 (en) Antibodies for the treatment and diagnosis of pseudomonas aeruginosa infections
SE8705137D0 (sv) Diagnostic method for primary biliary cirrhosis and antibodies suitable to be used in certain versions of the method
EP0554670A3 (en) Specific antibodies against activated platelets, their production and applications in diagnostics and therapeutics
ITBZ930044A0 (it) Procedimento per la ricerca di anticorpi anti-endomisio umani.
ES2088820B1 (es) Anticuerpos monoclonales antineumolisina.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 610447

Country of ref document: ES